Gemifloxacin is effective in experimental pneumococcal meningitis

Antimicrob Agents Chemother. 2000 Mar;44(3):767-70. doi: 10.1128/AAC.44.3.767-770.2000.

Abstract

In a rabbit model of Streptococcus pneumoniae meningitis, 5 mg of gemifloxacin mesylate (SB-265805) per kg/h reduced the bacterial titers in cerebrospinal fluid (CSF) almost as rapidly as 10 mg of ceftriaxone per kg/h (Deltalog CFU/ml/h +/- standard deviation [SD], -0.25 +/- 0.09 versus -0.38 +/- 0.11; serum and CSF concentrations of gemifloxacin were 2.1 +/- 1.4 mg/liter and 0.59 +/- 0.38 mg/liter, respectively, at 24 h). Coadministration of 1 mg of dexamethasone per kg did not affect gemifloxacin serum and CSF levels (2.7 +/- 1.4 mg/liter and 0.75 +/- 0.34 mg/liter, respectively, at 24 h) or activity (Deltalog CFU/ml/h +/- SD, -0.26 +/- 0.11).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Infective Agents / pharmacokinetics
  • Anti-Infective Agents / therapeutic use*
  • Ceftriaxone / therapeutic use
  • Cephalosporins / therapeutic use
  • Cerebrospinal Fluid / immunology
  • Cerebrospinal Fluid / microbiology
  • Disease Models, Animal
  • Fluoroquinolones*
  • Gemifloxacin
  • Hippocampus / pathology
  • Meningitis, Pneumococcal / drug therapy*
  • Meningitis, Pneumococcal / microbiology
  • Meningitis, Pneumococcal / pathology
  • Microbial Sensitivity Tests
  • Naphthyridines / pharmacokinetics
  • Naphthyridines / therapeutic use*
  • Neurons / pathology
  • Rabbits
  • Streptococcus pneumoniae / isolation & purification

Substances

  • Anti-Infective Agents
  • Cephalosporins
  • Fluoroquinolones
  • Naphthyridines
  • Ceftriaxone
  • Gemifloxacin